Search

Displaying results 6331 - 6340 of 10000 in total
  1. Drug

    Foscarbidopa

    go.drugbank.com/drugs/DB16171
    Approved

    Foscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult

  2. Drug

    TT 173

    go.drugbank.com/drugs/DB17717
    Investigational

    TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental

  3. Drug

    Octopamine

    go.drugbank.com/drugs/DB13251
    Experimental

    Octopamine is structurally similar to norepinephrine. It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World Anti-doping Agency (WADA) as of 2014.

  4. Drug

    Inarigivir soproxil

    go.drugbank.com/drugs/DB15063
    Investigational

    Inarigivir soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic

  5. Drug

    Simurosertib

    go.drugbank.com/drugs/DB16330
    Investigational

    Simurosertib is under investigation in clinical trial NCT03261947 (A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal

  6. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants

  7. Drug

    BMS-986104

    go.drugbank.com/drugs/DB15214
    Investigational

    BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

  8. Drug

    ABX-PTH

    go.drugbank.com/drugs/DB05883
    Experimental

    This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.

  9. Drug

    2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester

    go.drugbank.com/drugs/DB08261
    Experimental

    This drug targets the protein neocarzinostatin. … This compound belongs to the naphthalenecarboxylic acids and derivatives. These are compounds containing a napthalene moiety with a ring carbon which bears a carboxylic acid group or a derivative.

  10. Drug

    N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide

    go.drugbank.com/drugs/DB03456
    Experimental

    This compound belongs to the n-acyl-alpha amino acids and derivatives. … It is known to target cathepsin K.